MentalHealthDaily

Brain Gene Editing with CRISPR-Cas9 RNPs as Non-Viral Vector Alternative in Mice (2023 Study)

by GLOOM

CRISPR-Cas9 technology, a powerful tool for gene editing, has made significant strides in therapeutic applications, especially within the central nervous system (CNS). A recent study highlights the potential of non-viral delivery of CRISPR-Cas9 ribonucleoproteins (RNPs) into the mouse striatum, offering a promising alternative to viral vector-based delivery. Highlights: Non-Viral Delivery of CRISPR-Cas9: The study focuses …

Dopamine & Social Status vs. Stress Responses in Mice (2023 Study)

by GLOOM

Social hierarchies are not just a human phenomenon; they’re prevalent in the animal kingdom too, particularly among social creatures like mice. A groundbreaking study on isogenic C57BL/6 mice has shed light on the intricate mechanisms that govern social hierarchy, particularly focusing on the role of dopamine and stress response. This discovery not only enhances our …

Lifetime Major Depression Linked to Increased Activation of Amygdala & DLPFC (2024 Study)

by GLOOM

Major depressive disorder (MDD) is a prevalent mental health condition marked by significant social and economic impacts. Recent research has advanced our understanding of MDD, particularly its association with brain activity and connectivity. A new study examined the relationship between lifetime MDD (LMDD) and brain activation in response to fearful faces, focusing on the amygdala …

Genetic Risk for Low Vitamin D Linked to Lower Social Motivation in First-Episode Psychosis (2024 Study)

by GLOOM

Recent research reveals a notable association between vitamin D levels and the severity of negative symptoms in individuals with first-episode psychosis (FEP). A new study explored the genetic predisposition towards lower vitamin D levels and its impact on symptom severity in schizophrenia and related disorders. Highlights: Vitamin D & Psychosis Connection: Lower levels of vitamin …

Genetics & Age-Related Cognitive Decline: Insights from TOMORROW Trial (2024 Study)

by GLOOM

In a study utilizing data from the TOMMORROW trial, researchers have embarked on a novel exploration of genetic associations with cognitive change in older individuals. Employing a genome-wide association study (GWAS) approach, they’ve identified specific genetic variants linked to cognitive dynamics, providing new insights into the genetic underpinnings of cognitive change with aging. Highlights: Novel …

Proton Pump Inhibitors (PPIs) May Treat OCD via Neuronal pH & Dopamine Modulation (2024 Study)

by GLOOM

Obsessive-compulsive disorder (OCD), a prevalent neuropsychiatric condition, presents significant treatment challenges due to its varied symptom patterns and poor response to traditional medications. Recent research has revealed a novel approach to treating OCD, focusing on the interplay between dopamine D2 receptor (D2R) agonists and proton pump inhibitors (PPIs). Highlights: OCD’s Complex Treatment Landscape: Traditional treatments …

D-Cycloserine Targets the NMDA Receptors to Enhance Synpatic Plasticity in Hippocampus (2024 Study)

by GLOOM

In the complex and evolving field of neuroscience, the role of synaptic plasticity in psychiatric disorders has garnered significant attention. d-Cycloserine (DCS), a partial agonist of the N-methyl-D-aspartate receptor (NMDAR), emerges as a key player in potentially revolutionizing treatment approaches. Highlights: d-Cycloserine (DCS): Initially an antimicrobial agent, DCS is now known for its role as …